Compass Pathways PLC (NASDAQ: CMPS) is a clinical-stage mental health company developing psilocybin-based treatments for psychiatric conditions. The company generates no product revenue and funds operations through equity issuances, including ordinary share offerings under an at-the-market facility, and research and development tax incentives from UK corporate tax authorities. Its lead candidate, COMP360, is a proprietary psilocybin formulation in clinical development for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). Incorporated in England and Wales, Compass has filed patents covering COMP360's use across a range of indications including TRD, PTSD, anxiety disorders, eating disorders, migraines, bipolar disorder, substance use disorder, ADHD, and autism spectrum disorder, with patent protection extending to approximately 2040 to 2041. In the fourth quarter of 2024, the company announced a strategic reorganization, stopping all non-COMP360 preclinical and discovery work to concentrate resources on COMP360. The company has accumulated a deficit and has operated at a loss since inception.

Revenue model

Compass Pathways has no product revenue as of the 10-K filed 2026-03-24. The company finances operations through equity issuances, including ordinary shares issued under an at-the-market facility and warrant issuances, and receives R&D tax incentives from UK tax authorities due to its corporate tax domicile in the United Kingdom.

Products and services

COMP360 is the company's sole active therapeutic candidate, a proprietary psilocybin formulation targeting the 5-HT2A receptor. Clinical development focuses on treatment-resistant depression (TRD) and PTSD. Patents filed cover potential use across anxiety disorders, eating disorders, migraines, bipolar disorder, substance use disorder, ADHD, and autism spectrum disorder. Following a Q4 2024 strategic reorganization, all non-COMP360 preclinical and discovery programs were discontinued. The company also employs digital technologies for clinical trial data collection, patient and healthcare professional education, and digital phenotyping.

Customers and end markets

End markets are psychiatric patients with treatment-resistant depression and PTSD. Reimbursement would depend on governmental authorities, private health insurers, and other payors. No commercial sales have occurred. Coverage and reimbursement pathways remain unestablished, as psilocybin treatments are currently precluded from reimbursement in the US and COMP360 has not received regulatory approval.

Value-chain role

Compass Pathways operates as a clinical-stage drug developer, conducting research and clinical trials rather than manufacturing or distributing commercial products. It relies on third-party service vendors for portions of its IT infrastructure and digital technology services used in clinical trials. Academic collaborations with the University of Reading, University of Southampton, and University of Cardiff support mechanistic research into COMP360.

Geographic exposure

Compass Pathways is incorporated in England and Wales and is subject to UK corporate taxation. Patent applications for COMP360 indications have been filed in Australia, Canada, China, the European Patent Office, Hong Kong, Japan, South Korea, Taiwan, and the United States. Clinical development has a presence in both the US and Europe, with reimbursement risk cited in both geographies.

Source: SEC 10-K, filed 2026-03-24

Industry: Pharmaceutical Preparations Peers: Adaptimmune Therapeutics PLC Bicycle Therapeutics PLC Centessa Pharmaceuticals PLC Exscientia plc Immunocore Holdings PLC Myovant Sciences Ltd.